Pseudomonas aeruginosa serious infections: Mono or combination antimicrobial therapy?

Matteo Bassetti, Elda Righi, Claudio Viscoli

Research output: Contribution to journalArticlepeer-review


P. aeruginosa is a serious cause of infection with reported rates of mortality being up to 61%. Several studies evidenced a correlation between hospital mortality due to P. aeruginosa bloodstream infections and an inappropriate antimicrobial treatment. Increasing resistance in P. aeruginosa isolates complicates the selection of adequate empirical therapy in severe infections and P. aeruginova is often indistinguishable from other gram-negative bacterial infections. For these reasons, present guidelines for the treatment of suspected P. aeruginosa bacteraernia recommend the rapid introduction of empirical antimicrobial therapy that includes at least one antipseudomonal agent until having microbiological results. Current consensus favours the use of empirical combination, balancing the potential for greater toxicity against the lower emergence of antimicrobial resistance and the greater killing that might be achieved by combination therapies acting synergistically. Advantages and disadvantages of combination therapy towards monotherapy for P. aeruginosa severe infections, current antibiotics used for P. aeruginosa severe infections and main studies published on this issue are reviewed.

Original languageEnglish
Pages (from-to)517-522
Number of pages6
JournalCurrent Medicinal Chemistry
Issue number5
Publication statusPublished - Feb 2008


  • Aminoglycosides
  • Antibiotic
  • Beta-lactam
  • Combination
  • Flouroquinolones
  • Infection
  • P. aeruginosa
  • Treatment

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology


Dive into the research topics of 'Pseudomonas aeruginosa serious infections: Mono or combination antimicrobial therapy?'. Together they form a unique fingerprint.

Cite this